Compounds > salarin c
Page last updated: 2024-10-15

salarin c

Description

salarin C: has antineoplastic activity; isolated from the sponge Fascaplysinopsis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID155288808
MeSH IDM0573363

Synonyms (2)

Synonym
salarin c
[(e)-4-[3-[(2z,13z,15e)-9-(acetylcarbamoyloxy)-3,18-dimethyl-12-oxo-7,11,19-trioxa-20-azatricyclo[15.2.1.06,8]icosa-1(20),2,13,15,17-pentaen-10-yl]oxiran-2-yl]but-3-enyl] octanoate

Treatment

ExcerptReference
"Salarin C-treated K562 cells underwent apoptotic death as monitored by cell-cycle analysis, annexin V/propidium iodide staining, cleavage of poly-ADP-ribose polymerase (PARP) and caspase 3, and caspase 9 levels."( Salarin C, a member of the salarin superfamily of marine compounds, is a potent inducer of apoptosis.
Ben-Califa, N; Bishara, A; Kashman, Y; Neumann, D, 2012)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiazoles
[no description available]		2.41101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.1310methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
bortezomib
[no description available]		2.1310amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Granulocytic Leukemia, Chronic
[description not available]		02.5220
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		02.5220